Safety and efficacy of four drug regimens versus standard-of-care for the treatment of symptomatic outpatients with COVID-19: A randomised, open-label, multi-arm, phase 2 clinical trial

{ 'indexed': {'date-parts': [[2022, 11, 2]], 'date-time': '2022-11-02T04:50:30Z', 'timestamp': 1667364630222}, 'reference-count': 45, 'publisher': 'Elsevier BV', 'license': [ { 'start': { 'date-parts': [[2022, 12, 1]], 'date-time': '2022-12-01T00:00:00Z', 'timestamp': 1669852800000}, 'content-version': 'tdm', 'delay-in-days': 0, 'URL': 'https://www.elsevier.com/tdm/userlicense/1.0/'}, { 'start': { 'date-parts': [[2022, 10, 12]], 'date-time': '2022-10-12T00:00:00Z', 'timestamp': 1665532800000}, 'content-version': 'vor', 'delay-in-days': 0, 'URL': 'http://creativecommons.org/licenses/by/4.0/'}], 'content-domain': { 'domain': ['thelancet.com', 'elsevier.com', 'sciencedirect.com'], 'crossmark-restriction': True}, 'published-print': {'date-parts': [[2022, 12]]}, 'DOI': '10.1016/j.ebiom.2022.104322', 'type': 'journal-article', 'created': {'date-parts': [[2022, 11, 1]], 'date-time': '2022-11-01T17:38:01Z', 'timestamp': 1667324281000}, 'page': '104322', 'update-policy': 'http://dx.doi.org/10.1016/elsevier_cm_policy', 'source': 'Crossref', 'is-referenced-by-count': 0, 'title': 'Safety and efficacy of four drug regimens versus standard-of-care for the treatment of ' 'symptomatic outpatients with COVID-19: A randomised, open-label, multi-arm, phase 2 clinical ' 'trial', 'prefix': '10.1016', 'volume': '86', 'author': [ { 'ORCID': 'http://orcid.org/0000-0001-7866-2651', 'authenticated-orcid': False, 'given': 'Nomathemba', 'family': 'Chandiwana', 'sequence': 'first', 'affiliation': []}, {'given': 'Chelsea', 'family': 'Kruger', 'sequence': 'additional', 'affiliation': []}, {'given': 'Hilary', 'family': 'Johnstone', 'sequence': 'additional', 'affiliation': []}, {'given': 'Mohamed Farouk', 'family': 'Chughlay', 'sequence': 'additional', 'affiliation': []}, {'given': 'Chung', 'family': 'Ju', 'sequence': 'additional', 'affiliation': []}, {'given': 'Byungsu', 'family': 'Kim', 'sequence': 'additional', 'affiliation': []}, {'given': 'Yengiwe', 'family': 'Dineka', 'sequence': 'additional', 'affiliation': []}, {'given': 'Sarah', 'family': 'Arbe-Barnes', 'sequence': 'additional', 'affiliation': []}, {'given': 'Robert', 'family': 'Miller', 'sequence': 'additional', 'affiliation': []}, {'given': 'Andrew', 'family': 'Owen', 'sequence': 'additional', 'affiliation': []}, {'given': 'Andrew', 'family': 'Hill', 'sequence': 'additional', 'affiliation': []}, {'given': 'Daniel', 'family': 'Windgassen', 'sequence': 'additional', 'affiliation': []}, {'given': 'Nada', 'family': 'Abla', 'sequence': 'additional', 'affiliation': []}, {'given': 'Anne Claire', 'family': 'Marrast', 'sequence': 'additional', 'affiliation': []}, {'given': 'Stephan', 'family': 'Duparc', 'sequence': 'additional', 'affiliation': []}, { 'given': 'Willem Daniel', 'family': 'Francois Venter', 'sequence': 'additional', 'affiliation': []}], 'member': '78', 'reference': [ { 'key': '10.1016/j.ebiom.2022.104322_bib1', 'series-title': 'Coronavirus resource center', 'year': '2021'}, { 'key': '10.1016/j.ebiom.2022.104322_bib2', 'article-title': 'Post-COVID syndrome in non-hospitalised patients with COVID-19: a ' 'longitudinal prospective cohort study', 'volume': '6', 'author': 'Augustin', 'year': '2021', 'journal-title': 'Lancet Reg Health Eur'}, { 'key': '10.1016/j.ebiom.2022.104322_bib3', 'doi-asserted-by': 'crossref', 'first-page': '1085', 'DOI': '10.3851/IMP2128', 'article-title': 'Effect of oseltamivir, zanamivir or oseltamivir-zanamivir combination ' 'treatments on transmission of influenza in households', 'volume': '17', 'author': 'Carrat', 'year': '2012', 'journal-title': 'Antivir Ther'}, { 'key': '10.1016/j.ebiom.2022.104322_bib4', 'doi-asserted-by': 'crossref', 'first-page': '2149', 'DOI': '10.1001/jama.2020.22813', 'article-title': 'Therapy for early COVID-19: a critical need', 'volume': '324', 'author': 'Kim', 'year': '2020', 'journal-title': 'JAMA'}, { 'key': '10.1016/j.ebiom.2022.104322_bib5', 'doi-asserted-by': 'crossref', 'DOI': '10.12659/MSM.935952', 'article-title': 'Editorial: current status of oral antiviral drug treatments for ' 'SARS-CoV-2 infection in non-hospitalized patients', 'volume': '28', 'author': 'Parums', 'year': '2022', 'journal-title': 'Med Sci Monit'}, { 'key': '10.1016/j.ebiom.2022.104322_bib6', 'series-title': 'Therapeutic management of nonhospitalized adults with COVID-19', 'year': '2021'}, { 'key': '10.1016/j.ebiom.2022.104322_bib7', 'doi-asserted-by': 'crossref', 'first-page': '2697', 'DOI': '10.1136/bmj.n2697', 'article-title': 'Covid-19: UK becomes first country to authorise antiviral molnupiravir', 'volume': '375', 'author': 'Mahase', 'year': '2021', 'journal-title': 'BMJ'}, { 'key': '10.1016/j.ebiom.2022.104322_bib8', 'doi-asserted-by': 'crossref', 'first-page': '775', 'DOI': '10.1002/cpt.1909', 'article-title': 'Prioritization of anti-SARS-Cov-2 drug repurposing opportunities based ' 'on plasma and target site concentrations derived from their established ' 'human pharmacokinetics', 'volume': '108', 'author': 'Arshad', 'year': '2020', 'journal-title': 'Clin Pharmacol Ther'}, { 'key': '10.1016/j.ebiom.2022.104322_bib9', 'doi-asserted-by': 'crossref', 'first-page': '8', 'DOI': '10.1016/j.pt.2020.10.003', 'article-title': 'Repurposing antimalarials to tackle the COVID-19 pandemic', 'volume': '37', 'author': 'Krishna', 'year': '2021', 'journal-title': 'Trends Parasitol'}, { 'key': '10.1016/j.ebiom.2022.104322_bib10', 'doi-asserted-by': 'crossref', 'first-page': '509', 'DOI': '10.1038/s41586-020-2787-6', 'article-title': 'Animal models for COVID-19', 'volume': '586', 'author': 'Munoz-Fontela', 'year': '2020', 'journal-title': 'Nature'}, { 'key': '10.1016/j.ebiom.2022.104322_bib11', 'doi-asserted-by': 'crossref', 'first-page': '70', 'DOI': '10.1186/1475-2875-12-70', 'article-title': 'Safety and efficacy of pyronaridine-artesunate in uncomplicated acute ' 'malaria: an integrated analysis of individual patient data from six ' 'randomized clinical trials', 'volume': '12', 'author': 'Duparc', 'year': '2013', 'journal-title': 'Malar J'}, { 'key': '10.1016/j.ebiom.2022.104322_bib12', 'doi-asserted-by': 'crossref', 'first-page': '260', 'DOI': '10.1186/1475-2875-11-260', 'article-title': 'Clinical tolerability of artesunate-amodiaquine versus comparator ' 'treatments for uncomplicated falciparum malaria: an individual-patient ' 'analysis of eight randomized controlled trials in sub-Saharan Africa', 'volume': '11', 'author': 'Zwang', 'year': '2012', 'journal-title': 'Malar J'}, { 'key': '10.1016/j.ebiom.2022.104322_bib13', 'doi-asserted-by': 'crossref', 'first-page': '449', 'DOI': '10.2183/pjab.93.027', 'article-title': 'Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase', 'volume': '93', 'author': 'Furuta', 'year': '2017', 'journal-title': 'Proc Jpn Acad Ser B Phys Biol Sci'}, { 'key': '10.1016/j.ebiom.2022.104322_bib14', 'doi-asserted-by': 'crossref', 'first-page': '94', 'DOI': '10.1016/j.antiviral.2014.07.014', 'article-title': 'Nitazoxanide: a first-in-class broad-spectrum antiviral agent', 'volume': '110', 'author': 'Rossignol', 'year': '2014', 'journal-title': 'Antiviral Res'}, { 'key': '10.1016/j.ebiom.2022.104322_bib15', 'doi-asserted-by': 'crossref', 'first-page': '1039', 'DOI': '10.1097/QAD.0000000000001020', 'article-title': 'Interferon-free treatment with sofosbuvir/daclatasvir achieves ' 'sustained virologic response in 100% of HIV/hepatitis C ' 'virus-coinfected patients with advanced liver disease', 'volume': '30', 'author': 'Mandorfer', 'year': '2016', 'journal-title': 'AIDS'}, { 'key': '10.1016/j.ebiom.2022.104322_bib16', 'doi-asserted-by': 'crossref', 'DOI': '10.1371/journal.pntd.0007072', 'article-title': 'Yellow fever virus is susceptible to sofosbuvir both in\xa0vitro and ' 'in\xa0vivo', 'volume': '13', 'author': 'de Freitas', 'year': '2019', 'journal-title': 'PLoS Negl Trop Dis'}, { 'key': '10.1016/j.ebiom.2022.104322_bib17', 'doi-asserted-by': 'crossref', 'first-page': '134', 'DOI': '10.1016/j.antiviral.2016.11.023', 'article-title': 'The FDA-approved drug sofosbuvir inhibits Zika virus infection', 'volume': '137', 'author': 'Bullard-Feibelman', 'year': '2017', 'journal-title': 'Antiviral Res'}, { 'key': '10.1016/j.ebiom.2022.104322_bib18', 'doi-asserted-by': 'crossref', 'first-page': '448', 'DOI': '10.1111/cbdd.13091', 'article-title': 'Sofosbuvir as treatment against dengue?', 'volume': '91', 'author': 'Gan', 'year': '2018', 'journal-title': 'Chem Biol Drug Des'}, { 'key': '10.1016/j.ebiom.2022.104322_bib19', 'doi-asserted-by': 'crossref', 'DOI': '10.1128/AAC.01389-18', 'article-title': 'Beyond members of the flaviviridae family, sofosbuvir also inhibits ' 'Chikungunya virus replication', 'volume': '63', 'author': 'Ferreira', 'year': '2019', 'journal-title': 'Antimicrobial Agents Chemother'}, { 'key': '10.1016/j.ebiom.2022.104322_bib20', 'first-page': '1192', 'article-title': 'Experimental treatment with favipiravir for COVID-19: an open-label ' 'control study', 'volume': '6', 'author': 'Cai', 'year': '2020', 'journal-title': 'Engineering (Beijing)'}, { 'key': '10.1016/j.ebiom.2022.104322_bib21', 'article-title': 'Favipiravir versus arbidol for clinical recovery rate in moderate and ' 'severe adult COVID-19 patients: a prospective, multicenter, open-label, ' 'randomized controlled clinical trial', 'volume': '12', 'author': 'Chen', 'year': '2021', 'journal-title': 'Front Pharmacol'}, { 'key': '10.1016/j.ebiom.2022.104322_bib23', 'doi-asserted-by': 'crossref', 'first-page': 'e108', 'DOI': '10.1002/cpmc.108', 'article-title': 'An in\xa0vitro microneutralization assay for SARS-CoV-2 serology and ' 'drug screening', 'volume': '58', 'author': 'Amanat', 'year': '2020', 'journal-title': 'Curr Protoc Microbiol'}, { 'key': '10.1016/j.ebiom.2022.104322_bib24', 'doi-asserted-by': 'crossref', 'first-page': '1', 'DOI': '10.1186/s12879-015-1330-0', 'article-title': 'Development of the Flu-PRO: a patient-reported outcome (PRO) instrument ' 'to evaluate symptoms of influenza', 'volume': '16', 'author': 'Powers', 'year': '2016', 'journal-title': 'BMC Infect Dis'}, { 'key': '10.1016/j.ebiom.2022.104322_bib25', 'series-title': 'WHO R&D Blueprint novel coronavirus COVID-19 therapeutic trial synopsis', 'year': '2020'}, { 'key': '10.1016/j.ebiom.2022.104322_bib26', 'doi-asserted-by': 'crossref', 'first-page': 'e192', 'DOI': '10.1016/S1473-3099(20)30483-7', 'article-title': 'A\xa0minimal common outcome measure set for COVID-19 clinical research', 'volume': '20', 'year': '2020', 'journal-title': 'Lancet Infect Dis'}, { 'key': '10.1016/j.ebiom.2022.104322_bib27', 'first-page': '746', 'article-title': 'An introduction to multiplicity issues in clinical trials: the what, ' 'why, when and how', 'volume': '46', 'author': 'Li', 'year': '2017', 'journal-title': 'Int J Epidemiol'}, { 'key': '10.1016/j.ebiom.2022.104322_bib28', 'doi-asserted-by': 'crossref', 'first-page': '85', 'DOI': '10.1016/j.antiviral.2018.03.003', 'article-title': 'Favipiravir as a potential countermeasure against neglected and ' 'emerging RNA viruses', 'volume': '153', 'author': 'Delang', 'year': '2018', 'journal-title': 'Antiviral Res'}, { 'key': '10.1016/j.ebiom.2022.104322_bib29', 'doi-asserted-by': 'crossref', 'first-page': '52', 'DOI': '10.1016/S2055-6640(20)30017-0', 'article-title': 'Review of safety and minimum pricing of nitazoxanide for potential ' 'treatment of COVID-19', 'volume': '6', 'author': 'Pepperrell', 'year': '2020', 'journal-title': 'J\xa0Virus Erad'}, { 'key': '10.1016/j.ebiom.2022.104322_bib30', 'doi-asserted-by': 'crossref', 'first-page': 'e877', 'DOI': '10.1097/MEG.0000000000002287', 'article-title': 'Safety and efficacy of sofosbuvir/ledipasvir and sofosbuvir/daclatasvir ' 'in the treatment of hepatitis C in patients with decompensated ' 'cirrhosis', 'volume': '33', 'author': 'El Kassas', 'year': '2021', 'journal-title': 'Eur J Gastroenterol Hepatol'}, { 'key': '10.1016/j.ebiom.2022.104322_bib31', 'doi-asserted-by': 'crossref', 'first-page': '357', 'DOI': '10.5009/gnl18269', 'article-title': 'High efficacy and safety of flat-dose ribavirin plus ' 'sofosbuvir/daclatasvir in genotype 3 cirrhotic patients', 'volume': '14', 'author': 'Pellicelli', 'year': '2020', 'journal-title': 'Gut Liver'}, { 'key': '10.1016/j.ebiom.2022.104322_bib32', 'doi-asserted-by': 'crossref', 'first-page': '263', 'DOI': '10.1111/jvh.13032', 'article-title': 'Safety and efficacy of combined sofosbuvir/daclatasvir treatment of ' 'children and adolescents with chronic hepatitis C Genotype 4', 'volume': '26', 'author': 'Abdel Ghaffar', 'year': '2019', 'journal-title': 'J\xa0Viral Hepat'}, { 'key': '10.1016/j.ebiom.2022.104322_bib33', 'doi-asserted-by': 'crossref', 'first-page': '1147', 'DOI': '10.1021/acsinfecdis.2c00091', 'article-title': 'Pyronaridine protects against SARS-CoV-2 infection in mouse', 'volume': '8', 'author': 'Puhl', 'year': '2022', 'journal-title': 'ACS Infect Dis'}, { 'key': '10.1016/j.ebiom.2022.104322_bib34', 'doi-asserted-by': 'crossref', 'first-page': '602', 'DOI': '10.1016/j.cmi.2021.12.026', 'article-title': 'Efficacy of favipiravir in adults with mild COVID-19: a randomized, ' 'double-blind, multicenter, placebo-controlled trial clinical trial', 'volume': '28', 'author': 'Bosaeed', 'year': '2022', 'journal-title': 'Clin Microbiol Infect'}, { 'key': '10.1016/j.ebiom.2022.104322_bib35', 'first-page': '12575', 'article-title': 'Phase 3 trial of coronavir (favipiravir) in patients with mild to ' 'moderate COVID-19', 'volume': '13', 'author': 'Ruzhentsova', 'year': '2021', 'journal-title': 'Am J Transl Res'}, { 'key': '10.1016/j.ebiom.2022.104322_bib36', 'article-title': 'Understanding the clinical utility of favipiravir (T-705) in ' 'coronavirus disease of 2019: a review', 'volume': '8', 'author': 'Srinivasan', 'year': '2021', 'journal-title': 'Ther Adv Infect Dis'}, { 'key': '10.1016/j.ebiom.2022.104322_bib37', 'doi-asserted-by': 'crossref', 'DOI': '10.1016/j.ejps.2020.105631', 'article-title': 'Clinical outcomes and plasma concentrations of baloxavir marboxil and ' 'favipiravir in covid-19 patients: an exploratory randomized, controlled ' 'trial', 'volume': '157', 'author': 'Lou', 'year': '2021', 'journal-title': 'Eur J Pharm Sci'}, { 'key': '10.1016/j.ebiom.2022.104322_bib38', 'doi-asserted-by': 'crossref', 'first-page': '3516', 'DOI': '10.1111/bcp.15227', 'article-title': 'Pharmacokinetic characterization of favipiravir in patients with ' 'COVID-19', 'volume': '88', 'author': 'Gulhan', 'year': '2022', 'journal-title': 'Br J Clin Pharmacol'}, { 'key': '10.1016/j.ebiom.2022.104322_bib39', 'doi-asserted-by': 'crossref', 'first-page': '2078', 'DOI': '10.1111/bcp.14619', 'article-title': 'Dose prediction for repurposing nitazoxanide in SARS-CoV-2 treatment or ' 'chemoprophylaxis', 'volume': '87', 'author': 'Rajoli', 'year': '2021', 'journal-title': 'Br J Clin Pharmacol'}, { 'key': '10.1016/j.ebiom.2022.104322_bib40', 'doi-asserted-by': 'crossref', 'first-page': '585', 'DOI': '10.1002/cpt.2463', 'article-title': 'An open label, adaptive, phase 1 trial of high-dose oral nitazoxanide ' 'in healthy volunteers: an antiviral candidate for SARS-CoV-2', 'volume': '111', 'author': 'Walker', 'year': '2022', 'journal-title': 'Clin Pharmacol Ther'}, { 'key': '10.1016/j.ebiom.2022.104322_bib41', 'doi-asserted-by': 'crossref', 'first-page': '753', 'DOI': '10.1093/jac/dkaa501', 'article-title': 'Sofosbuvir and daclatasvir for the treatment of COVID-19 outpatients: a ' 'double-blind, randomized controlled trial', 'volume': '76', 'author': 'Roozbeh', 'year': '2021', 'journal-title': 'J\xa0Antimicrob Chemother'}, { 'key': '10.1016/j.ebiom.2022.104322_bib42', 'doi-asserted-by': 'crossref', 'first-page': '758', 'DOI': '10.1093/jac/dkab433', 'article-title': 'Evaluation of the effect of sofosbuvir and daclatasvir in hospitalized ' 'COVID-19 patients: a randomized double-blind clinical trial (DISCOVER)', 'volume': '77', 'author': 'Mobarak', 'year': '2021', 'journal-title': 'J\xa0Antimicrob Chemother'}, { 'key': '10.1016/j.ebiom.2022.104322_bib43', 'doi-asserted-by': 'crossref', 'first-page': '3373', 'DOI': '10.1093/jac/dkaa332', 'article-title': 'Evaluation of the efficacy of sofosbuvir plus daclatasvir in ' 'combination with ribavirin for hospitalized COVID-19 patients with ' 'moderate disease compared with standard care: a single-centre, ' 'randomized controlled trial', 'volume': '75', 'author': 'Abbaspour Kasgari', 'year': '2020', 'journal-title': 'J\xa0Antimicrob Chemother'}, { 'key': '10.1016/j.ebiom.2022.104322_bib44', 'doi-asserted-by': 'crossref', 'first-page': '2227', 'DOI': '10.1002/jmv.26103', 'article-title': 'Clearance and persistence of SARS-CoV-2 RNA in patients with COVID-19', 'volume': '92', 'author': 'Carmo', 'year': '2020', 'journal-title': 'J\xa0Med Virol'}, { 'key': '10.1016/j.ebiom.2022.104322_bib45', 'doi-asserted-by': 'crossref', 'first-page': '62', 'DOI': '10.1016/j.ijid.2020.11.142', 'article-title': 'Efficacy and safety of favipiravir, an oral RNA-dependent RNA ' 'polymerase inhibitor, in mild-to-moderate COVID-19: a randomized, ' 'comparative, open-label, multicenter, phase 3 clinical trial', 'volume': '103', 'author': 'Udwadia', 'year': '2021', 'journal-title': 'Int J Infect Dis'}, { 'key': '10.1016/j.ebiom.2022.104322_bib46', 'doi-asserted-by': 'crossref', 'first-page': '509', 'DOI': '10.1056/NEJMoa2116044', 'article-title': 'Molnupiravir for oral treatment of covid-19 in nonhospitalized patients', 'volume': '386', 'author': 'Jayk Bernal', 'year': '2021', 'journal-title': 'N\xa0Engl J Med'}], 'container-title': 'eBioMedicine', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://api.elsevier.com/content/article/PII:S2352396422005047?httpAccept=text/xml', 'content-type': 'text/xml', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://api.elsevier.com/content/article/PII:S2352396422005047?httpAccept=text/plain', 'content-type': 'text/plain', 'content-version': 'vor', 'intended-application': 'text-mining'}], 'deposited': { 'date-parts': [[2022, 11, 1]], 'date-time': '2022-11-01T17:38:33Z', 'timestamp': 1667324313000}, 'score': 1, 'resource': {'primary': {'URL': 'https://linkinghub.elsevier.com/retrieve/pii/S2352396422005047'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2022, 12]]}, 'references-count': 45, 'alternative-id': ['S2352396422005047'], 'URL': 'http://dx.doi.org/10.1016/j.ebiom.2022.104322', 'relation': {}, 'ISSN': ['2352-3964'], 'subject': ['General Biochemistry, Genetics and Molecular Biology', 'General Medicine'], 'container-title-short': 'eBioMedicine', 'published': {'date-parts': [[2022, 12]]}, 'assertion': [ {'value': 'Elsevier', 'name': 'publisher', 'label': 'This article is maintained by'}, { 'value': 'Safety and efficacy of four drug regimens versus standard-of-care for the ' 'treatment of symptomatic outpatients with COVID-19: A randomised, open-label, ' 'multi-arm, phase 2 clinical trial', 'name': 'articletitle', 'label': 'Article Title'}, {'value': 'eBioMedicine', 'name': 'journaltitle', 'label': 'Journal Title'}, { 'value': 'https://doi.org/10.1016/j.ebiom.2022.104322', 'name': 'articlelink', 'label': 'CrossRef DOI link to publisher maintained version'}, {'value': 'article', 'name': 'content_type', 'label': 'Content Type'}, { 'value': '© 2022 The Authors. Published by Elsevier B.V.', 'name': 'copyright', 'label': 'Copyright'}], 'article-number': '104322'}